BRIDGEWATER, N.J.--(BUSINESS WIRE)--May 2, 2006--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN - News) today announced its financial results for the first quarter of 2006. For the three months ended March 31, 2006, Enzon reported net income of $21.7 million or $0.50 per diluted share, as compared to a net loss of $(3.1) million or $(0.07) per diluted share for the three months ended March 31, 2005. The March 31, 2006 net income included an investment gain of $13.8 million from the sale of shares of Nektar Therapeutics, Inc. (Nektar) common stock originally acquired as part of a legal settlement in January 2002.
